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Photochemically re-bridging disulﬁde bonds and
the discovery of a thiomaleimide mediated
photodecarboxylation of C-terminal cysteines†
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Described in this work is a novel method for photochemically
manipulating peptides and proteins via the installation of cysteine-
selective photoactive tags. Thiomaleimides, generated simply by
the addition of bromomaleimides to reduced disulﬁde bonds,
undergo [2 + 2] photocycloadditions to reconnect the crosslink
between the two cysteine residues. This methodology is demon-
strated to enable photoactivation of a peptide by macrocyclisation,
and reconnection of the heavy and light chains in an antibody
fragment to form thiol stable conjugates. Finally we report on an
intriguing thiomaleimide mediated photochemical decarboxylation
of C-terminal cysteines, discovered during this study.
The spatial and temporal control oﬀered by photochemistry,
along with its reagentless nature, presents powerful opportu-
nities for the highly targeted manipulation of biomolecules.
Research in this area has included the development of ‘photo-
click’ reactions for bioconjugation1 and methods to enable the
activation of proteins using light.2 Activators include photo-
chromic switches (such as azobenzenes) which have been used
as protein photoregulators and as switches for peptide activa-
tion.2b,3 Photolabile linkers, which upon release serve to
‘uncage’ to release the active species, have also been employed
for this purpose.2a,4 This controlled activation has application
in probing biological systems and in prodrugs, serving as a
light mediated triggering mechanism.
We envisaged an alternative mechanism of photoactivation,
which could be achieved by manipulating the disulfide bonds
in proteins using photoactive chemical tags (Scheme 1). Essen-
tial disulfides present a target that is known to be susceptible
to topological changes upon reduction, and thus deactivation.
Developing a method to photochemically rebridge such a
system would then trigger reactivation of the peptide, due to
reformation of the covalent cross-link and thus the bioactive
conformation. The following properties were proposed to be
useful in the design of such a system; (a) eﬃcient installation
of tags; (b) rapid and high yielding photochemical reaction;
and (c) minimal chemical perturbation upon irradiation, to
give greatest prospect of reforming the pharmacophore.
We have recently reported on the highly eﬃcient [2 + 2]
photodimerisation of thiomaleimides 1,5 generated readily by
the addition of bromomaleimides to thiols,6 that appeared to
meet these criteria well (Scheme 2). The reaction occurs
rapidly (5 min) at low dilution in buﬀered aqueous conditions,
quantitatively and both regio- and diastereo-selectively, to
generate cyclobutanes 2 which contain a rigid two carbon
bridge between the two thiols.
It was thus hypothesised that by coupling two modes of
reactivity of maleimides; selective bioconjugation to cysteine
residues and [2 + 2] photocyloadditions, a novel method of
photochemically manipulating disulfide bonds could be deve-
Scheme 1 The proposed method for photochemically activating pep-
tides by manipulating a disulﬁde bond.
Scheme 2 The photochemical dimerisation of thiomaleimides.5
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loped. Given the importance of disulfide bonds for the struc-
ture and function of a range of peptides and proteins, this
could oﬀer a method with diverse applications. A suitable
model to test this hypothesis was found in the small cyclic
peptide octreotide (3), a synthetic mimic of somatostatin used
for the treatment of neuroendocrine tumours.7 Reduction of
the single disulfide bond with TCEP was followed by modifi-
cation of each liberated cysteine with bromomaleimide 4.8 A
large excess of bromomaleimide 4 was employed to preclude
the possibility of any competing succinimide bridging8 i.e. one
bromomaleimide bridging both cysteines. The resulting
doubly modified bioconjugate was purified by HPLC and con-
firmed as 5 by MALDI mass spectrometry (ESI Fig. 1b and 2f†).
After isolation 5 was irradiated using a 5 W LED with a λmax of
365 nm to eﬀect photochemical re-bridging generating peptide
6 (Scheme 3). Though no mass change accompanies this reac-
tion, changes in the HPLC trace suggest completion within
2 minutes (ESI Fig. 1c†). No further changes are observed
upon prolonged irradiation. Notably the HPLC trace shows the
formation of multiple peaks, with four major products; MALDI
analysis revealed them to all have identical masses (m/z 1211,
ESI Fig. 2†). This outcome is likely due to the formation of a
mixture of the diﬀerent diastereo- and regio-isomers of
bridged conjugate 6; which is in contrast to the highly selective
intermolecular reaction.5 NMRs obtained on the crude conju-
gates 5 and 6 confirmed the expected loss of olefenic peaks
and appearance of cyclobutane C–H’s (ESI Fig. 3†). Further evi-
dence that photochemical cyclisation had occurred was gained
through testing the thiol reactivity of the conjugate before and
after irradiation. As expected, reaction of bis-thiomaleimide 5
with ethanedithiol resulted in conjugate addition;9 intrigu-
ingly this dithiol formed a bridge between the two maleimides
to generate expanded macrocyle 7. In contrast, after irradiation
of 5 the peptide was totally unreactive with ethanedithiol. This
confirmed the loss of the maleimide conjugate acceptors and
indicated complete conversion of open chain conjugate 5 to
bridged conjugate 6.
To test the hypothesis that octreotide could be photochemi-
cally activated by disulfide re-bridging, we tested native octreo-
tide 3 and conjugate 5 before and after irradiation in a
signalling assay. We transiently transfected human somato-
statin receptor 2 (SSTR2) into HEK293 cells and examined for
current activation after agonist application using whole-cell
patch clamping (ESI Fig. 6†).10 Concentrations were chosen to
achieve maximum activation with each peptide construct.
Octreotide 3 was found to be a potent agonist achieving signifi-
cant current even at 10 nM concentration. The acyclic peptide
conjugate 5 was essentially inactive even up to 1 µM, having
lost its structure and thus pharmacophore. Pleasingly, by irra-
diating the sample to generate cyclised peptide 6 activity
towards the SSTR2-G protein pathway is returned (Fig. 1). It is
notable that this activity is significantly attenuated, even at 100
nM concentration. This is likely due to a combination of the
deleterious eﬀect of the 2-carbon bridge on the highly con-
strained structure of octreotide (as recently described)10 and
the mixture of isomers obtained which will have varying activi-
ties. Despite this reduction in potency, this still represents a
photochemically mediated activation and the first example of
achieving this through rebridging of a disulfide bond.
Given the success of this [2 + 2] photocycloaddition on a
small peptide, which confirmed that the reaction could
be transferred from small molecule cysteine studies,5,6c we
wanted to test the reaction on a larger protein. We have
recently reported that bromomaleimides and other Next Gene-
ration Maleimides (NGMs) can be employed to site-selectively
modify antibodies and antibody fragments, to generate conju-
gates with powerful prospective therapeutic and diagnostic
applications.11 We thus decided to test the photochemical
rebridging strategy on a Fab antibody fragment. Fab fragments
contain one solvent accessible disulfide bond, cross-linking
the heavy and light chains. In the case of such proteins, the di-
sulfide bond is not crucial to activity as the structure is
retained in its absence due to suﬃcient intermolecular forces.
As such, photochemical rebridging in this context would not
Scheme 3 The tagging and photorebridging of Octreotide 3.
Fig. 1 Column chart showing maximum GIRK current activation upon
application of native octreotide 3 (10 nM), conjugate 5 (1 µM) and conju-
gate 6 (100 nM).
Communication Organic & Biomolecular Chemistry






















































































reactivate the antibody fragment; instead it would serve two
purposes. Firstly, it would challenge the capability of this
crosslinking reaction on a large biomolecule. Secondly it
would provide a method of photochemically stabilising protein
conjugates – by regenerating the interchain covalent bond
whilst removing the thiol instability.11d
The Fab fragment 8 of the therapeutic monoclonal antibody
Herceptin was chosen as the model protein.11e Reduction of
the disulfide bond by incubation with TCEP was followed by
bis-modification of the two liberated cysteines with an excess
of bromomaleimide 4. Subsequent irradiation at 365 nm
eﬀected successful re-bridging of the chains (Scheme 4).
SDS-PAGE was a highly eﬀective analysis method for this reac-
tion sequence (Fig. 2a). Lane 1 shows the ca. 50 kDa protein,
which upon reduction is observed as separate heavy and light
chains (lane 2) under these denaturing conditions. Bis-malei-
mide conjugate 10a retains these two bands as expected (lane
3), then upon irradiation the successful cross-linking of heavy
and light chains is observed to aﬀord bridged conjugate 11a
(lane 4). By densitometry analysis the yield of the cycloaddition
can be approximated at 85%. Retention of binding avidity of
10a and 11a to HER2 was confirmed using ELISA (Fig. 2c).
Notably complete thiol stability was shown by incubation of
Fig. 2 (a) Deconvoluted mass spectrum of conjugate 11a. Arrow denotes decarboxylative side reaction from Scheme 4. (b) SDS-PAGE analysis. Lane
1; native Her Fab 8. Lane 2; reduced Fab. Lane 3; conjugate 10a. Lane 4; conjugate 11a. For comparable SDS-PAGE and LCMS analysis of 10, 11b–c
see ESI.† (c). ELISA against HER2 for Native Her Fab 8, conjugate 10a and conjugate 11a.
Scheme 4 The photochemical re-bridging of a Fab fragment.
Organic & Biomolecular Chemistry Communication






















































































11a with DTT, BME and GSH, with no reactions observed. This
is an important feature of this photochemical re-bridging, as
thiol instability of antibody conjugates based on classical
maleimides has recently been demonstrated as a problem for
therapeutic applications.12
To demonstrate that this photo-crosslinking could be
carried out with protein conjugates towards functional appli-
cations, bromomaleimides 9a13 and 9b, with a short appended
oligoethylene glycol motif and a biotin respectively, were
employed. Successful re-bridging was observed in each case
(see ESI†). LCMS data for all conjugates confirmed the recon-
nection of the heavy and light chains to aﬀord 11a–c as the
major outcome of the irradiation (e.g. Fig. 2a). Intriguingly a
minor product observed by LCMS (marked by red arrow in
Fig. 2a) hinted at an unprecedented reaction of the C-terminal
cysteinyl-thiomaleimide on the light chain which was worthy
of further investigation. The loss of 76 Da relative to the MWt
of the unmodified light chain implied a decarboxylative
release of the thiomaleimide, to aﬀord enamides 12a–c
(Scheme 5).
This reaction would be related to decarboxylative processes
observed to occur on phthalimides containing pendent carb-
oxylic acids tethered to the imide nitrogen.14 If demonstrated
on thiomaleimides, this would represent a novel mode of
photoreactivity of maleimides. It would also oﬀer new opportu-
nities in phototriggered release of cargo from proteins contain-
ing C-terminal cysteines.
To confirm this reaction a small molecule study was carried
out. Irradiation of 13 (see ESI Scheme 2† for synthesis), in the
presence of sodium acetate as a base, resulted in complete
decarboxylation to produce ene-carbamate 16 in a 95% yield
(Scheme 6). This confirmed the discovery of this new malei-
mide mediated decarboxylative photocleavage. Mechanisti-
cally, a similar sequence can be postulated to that suggested
for the phthalimides;14b thus carboxylate 14 formation is fol-
lowed by absorption of a photon by the maleimide and sub-
sequent electron transfer to generate 15. Decarboxylation and
C–S bond fragmentation generates enamide 16. The expected
by-product would be a thiomaleimide anion; unfortunately
any attempts to isolate this component were unsuccessful,
suggesting oligomerisation or polymerisation was occurring.
The knowledge gained from the discovery of this novel reaction
is currently being used to inform the design of more general
maleimide based photocleavable linkers.
Conclusions
This work has described a strategy for the photochemically
triggered re-bridging of reduced disulfide bonds. This is
achieved by the installation of photoactive maleimide tags on
the two cysteine residues, which then undergo [2 + 2] photo-
cyloadditions to achieve the desired cross-linking. Disulfide
bonds play a key role in the structure and function of many
peptides and proteins, and thus it is envisaged that this
methodology could have broad applicability in photochemi-
cally manipulating such biomolecules. It is anticipated that
the eﬀect of the incorporated bridge on the activity will vary,
depending on the size and rigidity of the biomolecule, the role
of the disulfide bond in its structure and its proximity to the
pharmacophore.
In this study we have demonstrated application to the
photo-reactivation of Octreotide and the reconnection of heavy
and light chains of an antibody fragment to generate
thiol-stable antibody conjugates. During the course of the
work an interesting side reaction was also observed, leading
to the discovery of a novel decarboxylation reaction of
C-terminal cysteines. This reaction could represent a new
approach to photochemical uncaging, and is worthy of further
exploration. The high yields, biocompatibility, and fast reac-
tion times highlight the suitability of substituted maleimides
reagents as tools for the photochemical manipulation of
biomolecules.
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Scheme 5 A proposed photochemical side reaction leading to trace
formation of conjugates 12a–c.
Scheme 6 The photochemical decarboxylation of thio-maleimide 13
to produce enecarbamate 16.
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